

CONSIDERATIONS AS WE TREAT mCRPC EARLIER

Saturday 20 October 2018 • 13:00–14:30

Hall A1 - Room 15

Messe Munich • Munich, Germany

13:00–13:05	WELCOME AND INTRODUCTION <i>Professor Arnulf Stenzl (Germany) – Chair</i>
13:05–13:35	WHY SHOULD WE TREAT mCRPC EARLIER? <i>Professor Axel Heidenreich (Germany)</i>
13:35–13:55	WHAT ARE THE ENDOCRINE METABOLIC EFFECTS OF TREATING PROSTATE CANCER? <i>Professor Andrea Giustina (Italy)</i>
13:55–14:15	WHAT IS THE IMPACT ON THE PATIENT EXPERIENCE? <i>Professor Bertrand Tombal (Belgium)</i>
14:15–14:25	PANEL DISCUSSION AND AUDIENCE QUESTIONS <i>All Faculty</i>
14:25–14:30	SUMMARY AND CLOSE <i>Professor Arnulf Stenzl (Germany) – Chair</i>

mCRPC – metastatic castration-resistant prostate cancer

Astellas Pharma Europe LTD has organised and funded this symposium, selected the speakers and had joint input into the presentation content. It may include promotional messages related to Astellas product(s). Prescribing information related to Astellas product(s) is available upon request.